Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 1/2024

Open Access 01-12-2024 | Rheumatoid Arthritis | Review

Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care

Authors: Ola A. Al-Ewaidat, Moawiah M. Naffaa

Published in: Clinical and Experimental Medicine | Issue 1/2024

Login to get access

Abstract

Rheumatoid arthritis (RA) can independently increase the risk of stroke, affecting both young and adult RA patients. Recent attention has been drawn to the association between stroke and RA, supported by mounting evidence. Given that stroke is a significant and an urgent public health concern, this review aims to highlight the relationship between stroke and RA, covering mechanisms, underlying risk factors, early detection tools, and treatment implications. By uncovering the connection that links RA to stroke, we can pave the way for targeted healthcare practices and the development of preventive strategies for individuals with RA. Therefore, further research is imperative to deepen our understanding of this association and, ideally, guide treatment decisions for individuals at risk of both RA and stroke.
Literature
1.
2.
Collaborators GBDS. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820.CrossRef
3.
Feigin VL, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255–65.PubMedCrossRef
4.
5.
Nadareishvili Z, et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum. 2008;59(8):1090–6.PubMedPubMedCentralCrossRef
6.
Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006;2(2):99–106.PubMedCrossRef
7.
del Rincon ID, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737–45.PubMedCrossRef
8.
Kremers HM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58(8):2268–74.PubMedCrossRef
9.
10.
Masuda H, et al. Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. J Cardiol. 2014;64(5):366–70.PubMedCrossRef
11.
Semb AG, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis. 2010;69(11):1996–2001.PubMedCrossRef
12.
Sodergren A, et al. Increased incidence of stroke and impaired prognosis after stroke among patients with seropositive rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(4):641–4.PubMed
13.
14.
Watts RA, et al. Rheumatoid vasculitis: Becoming extinct? Rheumatology (Oxford). 2004;43(7):920–3.PubMedCrossRef
15.
16.
Dhillon N, Liang K. Prevention of stroke in rheumatoid arthritis. Curr Treat Options Neurol. 2015;17(7):356.PubMedCrossRef
17.
Damasio MB, et al. Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatr Radiol. 2010;40(6):985–98.PubMedCrossRef
18.
19.
Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35(1):8–17.PubMedCrossRef
20.
van Leuven SI, et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford). 2008;47(1):3–7.PubMedCrossRef
21.
Gonzalez-Gay MA, et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1219–23.PubMed
22.
Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361–403.PubMedCrossRef
23.
24.
25.
Zaman AG, et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000;149(2):251–66.PubMedCrossRef
26.
27.
28.
29.
Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev. 2006;5(5):331–7.PubMedCrossRef
30.
31.
Hallenbeck JM, Hansson GK, Becker KJ. Immunology of ischemic vascular disease: plaque to attack. Trends Immunol. 2005;26(10):550–6.PubMedCrossRef
32.
Lima DS, et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol. 2002;29(2):292–7.PubMed
33.
34.
Akhmedov A, et al. TNFalpha induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFalpha antibodies. Cardiovasc Res. 2022;118(1):254–66.PubMedCrossRef
35.
Suss P, et al. The joint-brain axis: insights from rheumatoid arthritis on the crosstalk between chronic peripheral inflammation and the brain. Front Immunol. 2020;11: 612104.PubMedPubMedCentralCrossRef
36.
Tam LH, et al. Effect of treat-to-target strategies aiming at remission of arterial stiffness in early rheumatoid arthritis: a randomized controlled study. J Rheumatol. 2018;45(9):1229–39.PubMedCrossRef
37.
Nishioku T, et al. Potential role for S100A4 in the disruption of the blood-brain barrier in collagen-induced arthritic mice, an animal model of rheumatoid arthritis. Neuroscience. 2011;189:286–92.PubMedCrossRef
38.
39.
Trommer K, et al. Increased incidence of stroke and transient ischemic attack in patients with rheumatoid arthritis and ankylosing spondylitis in Germany. Neuroepidemiology. 2021;55(2):162–70.PubMedCrossRef
40.
Boden-Albala B, Sacco RL. Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress. Curr Atheroscler Rep. 2000;2(2):160–6.PubMedCrossRef
41.
42.
He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. 2006;367(9507):320–6.PubMedCrossRef
43.
Hu X, et al. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci. 2017;38(1):33–40.PubMedCrossRef
44.
Li W, et al. Sleep duration and risk of stroke events and stroke mortality: a systematic review and meta-analysis of prospective cohort studies. Int J Cardiol. 2016;223:870–6.PubMedCrossRef
45.
46.
Yuan M, et al. Inflammatory bowel disease and risk of stroke: a meta-analysis of cohort studies. Int J Cardiol. 2016;202:106–9.PubMedCrossRef
47.
Parikh NS, Merkler AE, Iadecola C. Inflammation, autoimmunity, infection, and stroke: epidemiology and lessons from therapeutic intervention. Stroke. 2020;51(3):711–8.PubMedPubMedCentralCrossRef
48.
Agca R, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28.PubMedCrossRef
49.
50.
Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: a systematic review and meta-analysis. Stroke. 2016;47(4):943–50.PubMedCrossRef
51.
52.
Avina-Zubieta JA, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524–9.PubMedCrossRef
53.
Lee DH, et al. Association between ischemic stroke and seropositive rheumatoid arthritis in Korea: a nationwide longitudinal cohort study. PLoS ONE. 2021;16(5): e0251851.PubMedPubMedCentralCrossRef
54.
Solomon DH, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69(11):1920–5.PubMedCrossRef
55.
56.
57.
Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522–9.PubMedCrossRef
58.
Kang S, et al. associations between cardiovascular outcomes and rheumatoid arthritis: a nationwide population-based cohort study. J Clin Med. 2022;11(22):6812.PubMedPubMedCentralCrossRef
59.
van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7(7):391–8.PubMedCrossRef
60.
Barbarroja N, et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arter Thromb Vasc Biol. 2014;34(12):2706–16.CrossRef
61.
Taylor P, et al. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis. 2011;2011: 815038.PubMedPubMedCentral
62.
Bukhari M, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum. 2007;56(9):2929–35.PubMedPubMedCentralCrossRef
63.
Ronnelid J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005;64(12):1744–9.PubMedPubMedCentralCrossRef
64.
Gerli R, et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(5):724–5.PubMedCrossRef
65.
Rantapaa-Dahlqvist S, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–9.PubMedCrossRef
66.
Bartoloni E, et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev. 2012;11(11):815–20.PubMedCrossRef
67.
Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.PubMedCrossRef
68.
Nishimura K, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797–808.PubMedCrossRef
69.
Bizzaro N, et al. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem. 2007;53(8):1527–33.PubMedCrossRef
70.
van der Helm-van Mil AH, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006;54(4):1117–21.PubMedCrossRef
71.
Mackey RH, et al. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women’s health initiative. Arthritis Rheumatol. 2015;67(9):2311–22.PubMedPubMedCentralCrossRef
72.
Gomez-Vaquero C, et al. Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. Clin Rheumatol. 2012;31(1):35–9.PubMedCrossRef
73.
Curtis JR, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(12):1794–803.PubMedCrossRef
74.
Bakker MF, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012;71(10):1692–7.PubMedCrossRef
75.
Brahe CH, et al. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scand J Rheumatol. 2019;48(1):9–16.PubMedCrossRef
76.
Hambardzumyan K, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2015;74(6):1102–9.PubMedCrossRef
77.
Markusse IM, et al. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J Rheumatol. 2014;41(11):2114–9.PubMedCrossRef
78.
England BR, et al. 2019 update of the American college of rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken). 2019;71(12):1540–55.PubMedCrossRef
79.
Curtis JR, et al. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Curr Med Res Opin. 2019;35(9):1483–93.PubMedCrossRef
80.
van der Helm-van Mil AH, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford). 2013;52(5):839–46.PubMedCrossRef
81.
Curtis JR, et al. Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2018;77(3):386–92.PubMedCrossRef
82.
Curtis JR, et al. Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. Arthritis Res Ther. 2020;22(1):282.PubMedPubMedCentralCrossRef
83.
Lauper K, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the “JAK-pot” collaboration. Ann Rheum Dis. 2022;81(10):1358–66.PubMedCrossRef
84.
Mok CC, et al. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry. Rheumatology (Oxford). 2023; May 2:kead198.
85.
Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50(3):184–95.PubMedCrossRef
86.
Wang F, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404–19.PubMedCrossRef
87.
Genovese MC, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322(4):315–25.PubMedPubMedCentralCrossRef
88.
Charles-Schoeman C, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015;67(3):616–25.PubMedPubMedCentralCrossRef
89.
Charles-Schoeman C, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46(1):71–80.PubMedCrossRef
90.
Ytterberg SR, Bhatt DL, Connell CA. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. Reply N Engl J Med. 2022;386(18):1768.PubMed
91.
Khosrow-Khavar F, et al. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81(6):798–804.PubMedCrossRef
92.
Roubille C, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–9.PubMedCrossRef
93.
Ljung L, et al. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016;75(12):2087–94.PubMedCrossRef
94.
Dixon WG, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56(9):2905–12.PubMedPubMedCentralCrossRef
95.
Aletaha D, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.PubMedCrossRef
96.
97.
Quisi A, Alici G. The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Clin Lab Anal. 2018;32(9): e22598.PubMedPubMedCentralCrossRef
98.
Tomasson G, et al. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010;69(9):1649–54.PubMedCrossRef
99.
Tan EM, Smolen JS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med. 2016;213(10):1937–50.PubMedPubMedCentralCrossRef
100.
Edwards CJ, et al. The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart. 2007;93(10):1263–7.PubMedPubMedCentralCrossRef
101.
Holmqvist ME, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Int Med. 2010;268(6):578–85.CrossRef
102.
Kato H, Yamakawa M, Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol. 2000;27(8):1839–47.PubMed
103.
Majka DS, et al. Association of rheumatoid factors with subclinical and clinical atherosclerosis in African American Women: the multiethnic study of atherosclerosis. Arthritis Care Res (Hoboken). 2017;69(2):166–74.PubMedCrossRef
104.
105.
Zhu Z, et al. Serum rheumatoid factor levels at acute phase of ischemic stroke are associated with poststroke cognitive impairment. J Stroke Cerebrovasc Dis. 2019;28(4):1133–40.PubMedCrossRef
106.
Okada Y, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–81.PubMedCrossRef
107.
108.
109.
Jia Y, et al. Associations of rheumatoid factor, rheumatoid arthritis, and interleukin-6 inhibitor with the prognosis of ischemic stroke: a prospective multicenter cohort study and mendelian randomization analysis. Transl Stroke Res. 2023; May 31.
110.
111.
Han S, et al. Radial BMD and serum CTX-I can predict the progression of carotid plaque in rheumatoid arthritis: a 3-year prospective cohort study. Arthritis Res Ther. 2021;23(1):258.PubMedPubMedCentralCrossRef
112.
Pulito-Cueto V, et al. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(6):1201–5.PubMed
113.
Nikolopoulos D, et al. Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus. Ann Rheum Dis. 2023;82(5):646–57.PubMedCrossRef
114.
Pawluk H, et al. Effect of IL-6 and hsCRP serum levels on functional prognosis in stroke patients undergoing IV-thrombolysis: retrospective analysis. Clin Interv Aging. 2020;15:1295–303.PubMedPubMedCentralCrossRef
115.
Cimmino G, et al. Vitamin D inhibits IL-6 pro-atherothrombotic effects in human endothelial cells: a potential mechanism for protection against COVID-19 infection? J Cardiovasc Dev Dis. 2022;9(1):27.PubMedPubMedCentral
116.
117.
Hsu YH, et al. Anti-IL-20 monoclonal antibody inhibited inflammation and protected against cartilage destruction in murine models of osteoarthritis. PLoS ONE. 2017;12(4): e0175802.PubMedPubMedCentralCrossRef
118.
Kwan J, et al. IL-6 is a predictive biomarker for stroke associated infection and future mortality in the elderly after an ischemic stroke. Exp Gerontol. 2013;48(9):960–5.PubMedCrossRef
119.
120.
Penner LS, et al. Does coprescribing nonsteroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism? Br J Clin Pharmacol. 2022;88(11):4789–811.PubMedCrossRef
121.
Bresalier RS, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–102.PubMedCrossRef
122.
Baoqi Y, et al. Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis. Front Cardiovasc Med. 2021;8: 812631.PubMedCrossRef
123.
Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180: 114147.PubMedPubMedCentralCrossRef
124.
Curtis E, et al. Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):25–44.PubMedPubMedCentralCrossRef
125.
Moore N. Coronary risks associated with diclofenac and other NSAIDs: an update. Drug Saf. 2020;43(4):301–18.PubMedCrossRef
126.
Schink T, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: a multi-country European database study within the SOS Project. PLoS ONE. 2018;13(9): e0203362.PubMedPubMedCentralCrossRef
127.
Solomon SD, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–80.PubMedCrossRef
128.
Arber N, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885–95.PubMedCrossRef
129.
Gudbjornsson B, et al. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. Eur J Clin Pharmacol. 2010;66(6):619–25.PubMedCrossRef
130.
Gunter BR, et al. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42(1):27–38.PubMedCrossRef
131.
Zhang M, et al. NSAID-associated small intestinal injury: an overview from animal model development to pathogenesis, treatment, and prevention. Front Pharmacol. 2022;13: 818877.PubMedPubMedCentralCrossRef
132.
Varas-Lorenzo C, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011;20(12):1225–36.PubMedCrossRef
133.
Caughey GE, et al. Stroke risk and NSAIDs: an Australian population-based study. Med J Aust. 2011;195(9):525–9.PubMedCrossRef
134.
135.
Fanelli A, et al. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf. 2017;8(6):173–82.PubMedPubMedCentralCrossRef
136.
Masclee GMC, et al. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study from the SOS project. PLoS ONE. 2018;13(11): e0204746.PubMedPubMedCentralCrossRef
137.
White WB, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99(1):91–8.PubMedCrossRef
138.
McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9): e1001098.PubMedPubMedCentralCrossRef
139.
Solomon DH, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(12):3790–8.PubMedCrossRef
140.
Ferreira MB, et al. Sex differences in circulating proteins of patients with rheumatoid arthritis: a cohort study. Int J Rheum Dis. 2022;25(6):669–77.PubMedCrossRef
141.
Park K, Bavry AA. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014;10:25–32.PubMedPubMedCentral
142.
143.
Karimi A, et al. A comprehensive insight into effects of resveratrol on molecular mechanism in rheumatoid arthritis: a literature systematic review. Int J Rheum Dis. 2022;25(8):827–43.PubMedCrossRef
144.
Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arter Thromb Vasc Biol. 2011;31(5):986–1000.CrossRef
145.
Tsai TF, et al. Recommendations for psoriatic arthritis management: a joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology. J Formos Med Assoc. 2021;120(3):926–38.PubMedCrossRef
146.
147.
Andersohn F, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006;37(7):1725–30.PubMedCrossRef
148.
Anuncibay-Soto B, Font-Belmonte E, Fernandez-Lopez A. Combining anti-inflammatory and unfolding protein responses to fight stroke. Neural Regen Res. 2019;14(3):450–1.PubMedPubMedCentralCrossRef
149.
Bakhriansyah M, et al. Cyclo-oxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase. Fundam Clin Pharmacol. 2019;33(5):589–600.PubMedPubMedCentralCrossRef
150.
Jung JY, et al. Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: a prospective 4 year follow-up study. Int J Rheum Dis. 2019;22(8):1410–8.PubMedCrossRef
151.
Wu F, et al. Inflammation and oxidative stress: potential targets for improving prognosis after subarachnoid hemorrhage. Front Cell Neurosci. 2021;15: 739506.PubMedPubMedCentralCrossRef
152.
Gong L, et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genom. 2012;22(4):310–8.CrossRef
153.
Chen AI, et al. Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: a nationwide retrospective cohort study. Front Neurol. 2022;13:1018521.PubMedPubMedCentralCrossRef
154.
Danda D, et al. How safe is Celecoxib for Asian-Indian patients with rheumatic diseases? Int J Rheum Dis. 2013;16(1):24–9.PubMedCrossRef
155.
Lin YW, Wang JY, Lin MH. Stroke risk associated with NSAIDs uses in women with dysmenorrhea: a population-based cohort study. PLoS ONE. 2021;16(11): e0259047.PubMedPubMedCentralCrossRef
156.
Turner RJ, et al. A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke. Brain Res. 2011;1393:84–90.PubMedCrossRef
157.
Bruno G, et al. The role of substance P in cerebral ischemia. Int J Immunopathol Pharmacol. 2003;16(1):67–72.PubMedCrossRef
158.
O’Connor TM, et al. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201(2):167–80.PubMedCrossRef
159.
Janelsins BM, et al. Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood. 2013;121(15):2923–33.PubMedPubMedCentralCrossRef
160.
Goto T, Tanaka T. Tachykinins and tachykinin receptors in bone. Microsc Res Tech. 2002;58(2):91–7.PubMedCrossRef
161.
Munoz M, Covenas R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides. 2013;48:1–9.PubMedCrossRef
162.
Munoz M, Covenas R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014;46(7):1727–50.PubMedCrossRef
163.
Liu X, et al. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Artif Cells Nanomed Biotechnol. 2019;47(1):1628–34.PubMedCrossRef
164.
Barbosa-Cobos RE, et al. Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis. Clin Rheumatol. 2018;37(4):901–8.PubMedCrossRef
165.
Hong HS, Son Y. Substance P ameliorates collagen II-induced arthritis in mice via suppression of the inflammatory response. Biochem Biophys Res Commun. 2014;453(1):179–84.PubMedCrossRef
166.
Jiang MH, et al. Substance P induces M2-type macrophages after spinal cord injury. NeuroReport. 2012;23(13):786–92.PubMedCrossRef
167.
Origuchi T, et al. Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Mod Rheumatol. 2011;21(3):244–50.PubMedCrossRef
168.
169.
170.
Marshall KW, Chiu B, Inman RD. Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthritis Rheum. 1990;33(1):87–90.PubMedCrossRef
171.
172.
Putaala J, et al. Searching for explanations for cryptogenic stroke in the young: revealing the triggers, causes, and outcome (SECRETO): rationale and design. Eur Stroke J. 2017;2(2):116–25.PubMedPubMedCentralCrossRef
173.
Jin R, et al. Role of inflammation and its mediators in acute ischemic stroke. J Cardiovasc Transl Res. 2013;6(5):834–51.PubMedCrossRef
174.
Fatkhullina AR, Peshkova IO, Koltsova EK. The role of cytokines in the development of atherosclerosis. Biochemistry (Mosc). 2016;81(11):1358–70.PubMedCrossRef
175.
Lip GYH, et al. Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. Eur Heart J. 2022;43(26):2442–60.PubMedPubMedCentralCrossRef
176.
177.
Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis. 2004;63(8):952–5.PubMedPubMedCentralCrossRef
178.
Westerlind H, et al. The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis. Rheumatology (Oxford). 2023;62(6):2106–12.PubMedCrossRef
179.
Mantel A, et al. Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol. 2015;67(11):2845–54.PubMedCrossRef
180.
Westerlind H, et al. Anti-citrullinated protein antibody specificities, rheumatoid factor isotypes, and incident cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72(10):1658–67.PubMedCrossRef
181.
Meznerics FA, et al. Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis. Rheumatology (Oxford). 2023;62(6):2048–59.PubMedCrossRef
182.
Johnson TM, et al. Correlation of the multi-biomarker disease activity score with rheumatoid arthritis disease activity measures: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2019;71(11):1459–72.PubMedCrossRef
183.
Ortega-Hernandez OD, et al. Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Clin Rheumatol. 2009;28(7):767–75.PubMedCrossRef
184.
Arida A, et al. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19(7):1890.PubMedPubMedCentralCrossRef
185.
Giachi A, Cugno M, Gualtierotti R. Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis. Front Cardiovasc Med. 2022;9:1012661.PubMedPubMedCentralCrossRef
Metadata
Title
Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care
Authors
Ola A. Al-Ewaidat
Moawiah M. Naffaa
Publication date
01-12-2024
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2024
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-023-01288-7

Other articles of this Issue 1/2024

Clinical and Experimental Medicine 1/2024 Go to the issue

Research

Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis

Research

Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study

Review

Pathogenic role and clinical significance of neutrophils and neutrophil extracellular traps in idiopathic inflammatory myopathies

Research

FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis

Research

Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort

Research

Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits